

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Sacubitril valsartan for treating chronic heart failure [ID822]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis (Sacubitril valsartan) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Atrial Fibrillation Association • Arrhythmia Alliance • Black Health Agency • Blood Pressure UK • British Cardiac Patients Association • Cardiac Risk in the Young • Cardiomyopathy Association • Cardiovascular Care Partnership • Equalities National Council • HEART UK • Muslim Council of Britain • Network of Sikh Organisations • Pumping Marvellous Foundation • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiovascular Care • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Heart Rhythm Society • British Hypertension Society • British Nuclear Cardiology Society • British Society of Cardiovascular Imaging 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (eprosartan) • Actavis UK (candesartan, losartan potassium, lisinopril, telmisartan, valsartan) • Accord healthcare (losartan, irbesartan) • AstraZeneca (lisinopril) • Aurobindo Pharma-Milpharm (losartan, irbesartan, lisinopril, enalapril maleate) • Bayer (telmisartan) • Boehringer Ingelheim (telmisartan) • Bristol laboratories (captopril, losartan, lisinopril) • Bristol-Myers Squibb (captopril) • Daiichi Sankyo (olmesartan) • Dexcel pharma (losartan)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Society for Heart Failure • British Thoracic Society • College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Vascular Nurses • Society for Vascular Technology • UK Health Forum • UK Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Doncaster CCG • NHS England • NHS Surrey Heath CCG • Welsh Government 	<ul style="list-style-type: none"> • Martindale Pharma (captopril) • Merck Sharpe Dohme (enalapril maleate, losartan potassium, lisinopril) • Mylan (losartan, quinapril, valsartan) • Pfizer (losartan, quinapril) • Sanofi (captopril, irbesartan, ramipril) • Servier (perindopril arginine) • Takeda (azilsartan, candesartan cilexetil) • Teva (candesartan, losartan, lisinopril, quinapril, telmisartan, valsartan) • Wockhardt (losartan) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • <u>Antithrombotic Trialists' (ATT) Collaboration</u> • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts • Central Cardiac Audit Database • Cochrane Heart Group • Cochrane Peripheral Vascular Diseases Group • European Council for Cardiovascular Research • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Heart Research Fund • National Institute for Health Research • Wellcome Trust <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • BMJ Group • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.